We are excited to introduce the latest addition to our portfolio: ATLyphe, a preclinical stage biotechnology startup dedicated to enable safer hematopoietic cell transplantation for patients in need.
Together with their team, the co-founders Dres. Danielle Villars, Renier Myburgh and Maddalena Marconato are driving forward the development of their lead compound ALY117, a bispecific T cell engager, to transform the current approach to hematopoietic stem cell transplantation (HSCT).
HSCT can offer a potential cure for many non-malignant and malignant hematologic diseases such as AML. However, the current toxic conditioning regimens (composed of different chemotherapies) pose substantial risks for patients and impact HSCT success. ATLyphe’s bispecific T cell engager introduces a precision medicine approach. By leveraging antibody-derived specificity, it precisely targets and eliminates only those cells that require removal (i.e. stem cells), avoiding the systemic effects typically induced by chemotherapy-based conditioning. Furthermore, the incorporation of T cell-mediated cytotoxicity promises high efficiency, making it particularly interesting for patients with malignant disorders. In summary, ALY117 sits at the sweet spot between safety and efficacy. ATLyphe aims to integrate ALY117 into clinical practice, offering new hope to patients worldwide.
We look forward to supporting ATLyphe in their efforts to bring this novel and targeted conditioning to patients.
Besides being a USZ Startup, ATLyphe is a spin-off from ETH Zurich and from University of Zurich and is currently supported by Wyss Zurich.
More about ATLyphe AG